A necrodane monoterpenoid from Lavandula luisieri essential oil as a cell-permeable inhibitor of BACE-1, the β-secretase in Alzheimer's disease

Flavour and Fragrance Journal

Volumn 28, Issue 6, 2013, Pages 380-388

  Videira, Rita ^a,b   Castanheira, Pedro ^b   Grãos, Mário ^b   Salgueiro, Lígia ^a   Faro, Carlos ^b,c   Cavaleiro, Carlos ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b Biocant Center of Innovation in Biotechnology   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Alzheimer's disease; BACE 1; Cell permeable inhibitors; Lavandula luisieri; Necrodane monoterpenoids

Indexed keywords

ALZHEIMER'S DISEASE; BACE-1; CELL-PERMEABLE; LAVANDULA; MONOTERPENOIDS;

CELL CULTURE; CELL MEMBRANES; ENZYME INHIBITION; GAS CHROMATOGRAPHY; KETONES; NEURODEGENERATIVE DISEASES; OIL WELL TESTING; UNSATURATED COMPOUNDS;

ESSENTIAL OILS;

1 OCTEN 3 OL; 3 CARENE; BETA EUDESMOL; BETA SECRETASE 1; BORNEOL; CAMPHENE; CAMPHOR; CARYOPHYLLENE OXIDE; CINEOLE; ESSENTIAL OIL; HUMULENE; LIMONENE; LINALOOL; MYRCENE; OCIMENE; PARA CYMENE; PINENE; SABINENE; SPATHULENOL; T CADINOL; TERPENOID; TERPINEN 4 OL; TERPINENE; TERPINOLENE;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; FRACTIONATION; HYDROPHOBICITY; LAVANDULA LUISIERI; LAVENDER; MASS FRAGMENTOGRAPHY; NONHUMAN;

LAVANDULA;

EID: 84885865286     PISSN: 08825734     EISSN: 10991026     Source Type: Journal    
DOI: 10.1002/ffj.3156     Document Type: Article

References (30)

1. T. E. Golde. Alzheimer disease therapy: Can the amyloid cascade be halted? J. Clin. Invest. 2003, 111, 11.
2. L. Pastorino, K. P. Lu. Pathogenic mechanisms in Alzheimer's disease. Eur. J. Pharmacol. 2006, 545, 29.
3. S. Sinha, J. P. Anderson, R. Barbour, G. S. Basi, R. Caccavello, D. Davis, M. Doan, H. F. Dovey, N. Frigon, J. Hong, K. Jacobson-Croak, N. Jewett, P. Keim, J. Knops, I. Lieberburg, M. Power, H. Tan, G. Tatsuno, J. Tung, D. Schenk, P. Seubert, S. M. Suomensaari, S. Wang, D. Walker, J. Zhao, L. McConlogue, V. John. Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature 1999, 402, 537.
4. R. Vassar, B. D. Bennett, S. Babu-Khan, S. Kahn, E. A. Mendiaz, P. Denis, D. B. Teplow, S. Ross, P. Amarante, R. Loeloff, Y. Luo, S. Fisher, J. Fuller, S. Edenson, J. Lile, M. A. Jarosinski, A. L. Biere, E. Curran, T. Burgess, J. C. Louis, F. Collins, J. Treanor, G. Rogers, M. Citron. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286, 735.
5. W. Annaert, B. De Strooper. A cell biological perspective on Alzheimer's disease. Annu. Rev. Cell Dev. Biol. 2002, 18, 25.
6. C. Dash, A. Kulkarni, B. Dunn, M. Rao. Aspartic peptidase inhibitors: Implications in drug development. Crit. Rev. Biochem. Mol. Biol. 2003, 38, 89.
7. A. K. Ghosh, D. Shin, D. Downs, G. Koelsch, X. Lin, J. Ermolieff, J. Tang. Design of potent inhibitors for human brain Memapsin 2 (β-secretase). J. Am. Chem. Soc. 2000, 122, 3522.
8. L. Hong, R. T. Turner, G. Koelsch, A. K. Ghosh, J. Tang. Memapsin 2 (β-secretase) as a therapeutic target. Biochem. Soc. Trans. 2002, 30, 530.
9. S. Lefranc-Jullien, V. Lisowski, J. F. Hernandez, J. Martinez, F. Checler. Design and characterization of a new cell-permeant inhibitor of the β-secretase BACE1. Br. J. Pharmacol. 2005, 145, 228.
10. I. Hussain, J. Hawkins, D. Harrison, C. Hille, G. Wayne, L. Cutler, T. Buck, D. Walter, E. Demont, C. Howes, A. Naylor, P. Jeffrey, M. I. Gonzalez, C. Dingwall, A. Michel, S. Redshaw, J. B. Davis. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases β-cleavage of amyloid precursor protein and amyloid-β production in vivo. J. Neurochem. 2007, 100, 802.
11. S. Sankaranarayanan, M. A. Holahan, D. Colussi, M. C. Crouthamel, V. Devanarayan, J. Ellis, A. Espeseth, A. T. Gates, S. L. Graham, A. R. Gregro, D. Hazuda, J. H. Hochman, K. Holloway, L. Jin, J. Kahana, M. T. Lai, J. Lineberger, G. McGaughey, K. P. Moore, P. Nantermet, B. Pietrak, E. A. Price, H. Rajapakse, S. Stauffer, M. A. Steinbeiser, G. Seabrook, H. G. Selnick, X. P. Shi, M. G. Stanton, J. Swestock, K. Tugusheva, K. X. Tyler, J. P. Vacca, J. Wong, G. Wu, M. Xu, J. J. Cook, A. J. Simon. First demonstration of cerebrospinal fluid and plasma Aβ lowering with oral administration of a β-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J. Pharmacol. Exp. Ther. 2009, 328, 131.
12. M. Imanshahidi, H. Hosseinzadeh. The pharmacological effects of Salvia species on the central nervous system. Phytother. Res. 2006, 20, 427.
13. M. Miyazawa, H. Watanabe, K. Umemoto, H. Kameoka. Inhibition of acetylcholinesterase activity by essential oils of Mentha species. J. Agric. Food Chem. 1998, 46, 3431.
14. M. I. García-Vallejo, M. C. García-Vallejo, J. Sanz, M. Bernabe, A. Velasco-Negueruela. Necrodane (1, 2, 2, 3, 4-pentamethylcyclopentane) derivatives in Lavandula luisieri, new compounds to the plant kingdom. Phytochemistry 1994, 36, 43.
15. N. Baldovini, S. Lavoine-Hanneguelle, G. Ferrando, G. Dusart, L. Lizzani-Cuvelier. Necrodane monoterpenoids from Lavandula luisieri. Phytochemistry 2005, 66, 1651.
16. A. Gonzalez-Coloma, D. Martin-Benito, N. Mohamed, M. C. Garcia-Vallejo, A. C. Soria. Antifeedant effects and chemical composition of essential oils from different populations of Lavandula luisieri L. Biochem. Syst. Ecol. 2006, 34, 609.
17. S. Roller, N. Ernest, J. Buckle. The antimicrobial activity of high-necrodane and other lavender oils on methicillin-sensitive and methicillin-resistant Staphylococcus aureus (MSSA and MRSA). J. Alt. Compl. Med. 2009, 15, 275
18. F. Matos, M. G. Miguel, J. Duarte, F. Venancio, C. Moiteiro, A. I. D. Correia, A. C. Figueiredo, J. G. Barroso, L. G. Pedro. Antioxidant capacity of the essential oils from Lavandula luisieri, L. stoechas subsp. lusitanica, L. stoechas subsp. lusitanica x L. luisieri and L. viridis grown in Algarve (Portugal). J. Essent. Oil Res. 2009, 21, 327
19. M. Zuzarte, M. J. Goncalves, M. T. Cruz, C. Cavaleiro, J. Canhoto, S. Vaz, E. Pinto, L. Salgueiro. Lavandula luisieri essential oil as a source of antifungal drugs. Food Chem. 2012, 135, 1505
20. J. Ermolieff, J. A. Loy, G. Koelsch, J. Tang. Proteolytic activation of recombinant pro-memapsin 2 (pro-β-secretase) studied with new fluorogenic substrates. Biochemistry 2000, 39, 12450.
21. Council of Europe, EDQM. European Pharmacopoeia, European Directorate for the Quality of Medicines (EDQM): Strasbourg, 2007.
22. W. McLafferty. Wiley Registry of Mass Spectral Data 9th/NIST 08. Mass Spectral Library, 2009.
23. R. P. Adams, Identification of Essential Oil Components by Gas Chromatography/Mass Spectrometry. Allured Publishing: Carol Stream, 2007.
24. M. I. García-Vallejo. Aceites Esenciales de las Lavandulas Ibericas - Ensayo de la Quimiotaxonomia, PhD Thesis, Department of Plant Biology, University Complutense de Madrid, 1992.
25. S. Lavoine-Hanneguelle, H. Casabianca. New compounds from the essential oil and absolute of Lavandula luisieri L. JEOR 2004, 16, 445.
26. J. Sanz, A. C. Soria, M. C. García-Vallejo. Analysis of volatile components of Lavandula luisieri L. by direct thermal desorption-gas chromatography-mass spectrometry. J. Chromatogr. A 2004, 1024, 139.
27. P. J. Linstrom, W. G. Mallard. Eds., NIST Chemistry WebBook, NIST Standard Reference Database Number 69, National Institute of Standards and Technology, Gaithersburg MD, 20899, http://webbook.nist.gov (accessed 20/03/2013)
28. A. M. El-Sayed. The Pherobase: Database of Pheromones and Semiochemicals. 2012, http://www.pherobase.com (accessed 20/03/2013)
29. T. Acree, H. Arn. Flavornet and human odor space Datu Inc., 2004, http://www.flavornet.org (accessed 20/03/2013)
30. P. Weyerstahl, H. Marschall, K. Thefeld, G. C. Subba. Constituents of the essential oil from the rhizomes of Hedychium gardnerianum Roscoe. Flavour Fragr. J. 1998, 13, 377.